Skip to Content

Teva's Generics CEO Departure Cause for Concern

Pricing pressure in the generic drug market and anticipated generic competition on the one of the narrow-moat company's main drugs in 2017 makes the abrupt leadership change a concerning development at a critical time for the company.

Securities In This Article
Teva Pharmaceutical Industries Ltd ADR
(TEVA)

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

More in Stocks

About the Author

Michael Waterhouse

Sector Strategist
More from Author

Michael Waterhouse is a healthcare strategist for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. He covers specialty pharmaceutical and life science and diagnostic companies.

Before joining Morningstar in 2010, Waterhouse was a research biologist for the Centers for Disease Control and Prevention. He was also a volunteer in the Peace Corps.

Waterhouse holds a bachelor’s degree in biology from the University of Georgia. He also holds a master’s degree in business administration from the University of Minnesota, where he participated in the Carlson Funds Enterprise, a student managed investment fund.

Sponsor Center